International AIDS Vaccine Initiative, New York, NY, USA.
Tufts University School of Medicine, 145 Harrison Avenue, Boston, MA, 02111, USA.
Syst Rev. 2024 Aug 15;13(1):218. doi: 10.1186/s13643-024-02626-w.
Recent outbreaks of Ebola virus disease (EVD) and Marburg virus disease (MVD) in sub-Saharan Africa illustrate the need to better understand animal reservoirs, burden of disease, and human transmission of filoviruses. This protocol outlines a systematic literature review to assess the prevalence of filoviruses that infect humans in sub-Saharan Africa. A secondary aim is to qualitatively describe and evaluate the assays used to assess prevalence.
The data sources for this systematic review include PubMed, Embase, and Web of Science. Titles, abstracts, and full texts will be reviewed for inclusion by a primary reviewer and then by a team of secondary reviewers, and data will be extracted using a pre-specified and piloted data extraction form. The review will include human cross-sectional studies, cohort studies, and randomized controlled trials conducted in sub-Saharan Africa up until March 13, 2024 that have been published in peer-reviewed scientific journals, with no language restrictions. Prevalence will be stratified by pathogen, population, assay, and sampling methodology and presented in forest plots with estimated prevalence and 95% confidence intervals. If there are enough studies within a stratum, I statistics will be calculated (using R statistical software), and data will be pooled if heterogeneity is low. In addition, assays used to detect infection will be evaluated. All studies included in the review will be assessed for quality and risk of bias using the JBI Prevalence Critical Appraisal Tool and for certainty using the GRADE certainty ratings.
Accurately measuring the rate of exposure to filoviruses infecting humans in sub-Saharan Africa using prevalence provides an essential understanding of natural history, transmission, and the role of subclinical infection. This systematic review will identify research gaps and provide directions for future research seeking to improve our understanding of filovirus infections. Understanding the natural history, transmission, and the role of subclinical infection is critical for predicting the impact of an intervention on disease burden.
In accordance with the guidelines outlined in the PRISMA-P methodology, this protocol was registered with PROSPERO on April 7, 2023 (ID: CRD42023415358).
最近在撒哈拉以南非洲暴发的埃博拉病毒病（EVD）和马尔堡病毒病（MVD）表明，需要更好地了解动物宿主、疾病负担以及丝状病毒在人类中的传播。本方案概述了一项系统文献综述，以评估感染撒哈拉以南非洲人类的丝状病毒的流行率。次要目标是定性描述和评估用于评估流行率的检测方法。
本系统综述的数据来源包括 PubMed、Embase 和 Web of Science。将由主要审查员和一组次要审查员审查标题、摘要和全文，以确定是否纳入，并使用预先指定和试用的数据提取表提取数据。该综述将包括在撒哈拉以南非洲进行的已发表在同行评议科学期刊上的人类横断面研究、队列研究和随机对照试验，研究期限截至 2024 年 3 月 13 日，无语言限制。将按病原体、人群、检测方法和采样方法对流行率进行分层，并以估计的流行率和 95%置信区间呈现森林图。如果在一个分层中有足够的研究，将计算 I 统计量（使用 R 统计软件），如果异质性低，则将数据合并。此外，还将评估用于检测感染的检测方法。将使用 JBI 流行率批判性评价工具评估综述中包含的所有研究的质量和偏倚风险，并使用 GRADE 确定性评分评估其确定性。
使用流行率准确测量撒哈拉以南非洲感染人类的丝状病毒的暴露率，对于了解自然史、传播以及亚临床感染的作用至关重要。这项系统综述将确定研究差距，并为未来旨在提高我们对丝状病毒感染认识的研究提供方向。了解自然史、传播以及亚临床感染的作用对于预测干预对疾病负担的影响至关重要。
根据 PRISMA-P 方法学的指导原则，本方案于 2023 年 4 月 7 日在 PROSPERO 上进行了注册（编号：CRD42023415358）。
